AC
KZR

Apogem Capital’s Kezar Life Sciences KZR Stock Holding History

Apogem Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,332
Closed -$804K – 63
2022
Q3 		$804K Sell
9,332
-61
-0.6% -$5.93K 0.8% 34
2022
Q2 		$777K Buy
9,393
+7,191
+327% +$634K 0.7% 41
2022
Q1 		$366K Sell
2,202
-501
-19% -$71.9K 0.25% 116
2021
Q4 		$452K Sell
2,703
-2,132
-44% -$241K 0.3% 104
2021
Q3 		$418K Sell
4,835
-3,052
-39% -$202K 0.27% 123
2021
Q2 		$428K Buy
7,887
+2,120
+37% +$120K 0.27% 121
2021
Q1 		$344K Buy
+5,767
New +$337K 0.23% 133

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Apogem Capital's KZR Position: Q4 2022 in Review

Apogem Capital sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 9,332 shares — an estimated $804K sold.

Apogem Capital first reported a position in KZR in Q1 2021 and held it in 7 quarters. The position peaked at $804K in Q3 2022. 123 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • Apogem Capital reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 9,332 Kezar Life Sciences shares in Q4 2022, an estimated $804K.
  • Apogem Capital first reported a position in Kezar Life Sciences in Q1 2021 and held it in 7 quarters.
  • Apogem Capital's Kezar Life Sciences position peaked at $804K in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.